Search

Displaying results 971 - 980 of 2160 in total
  1. Drug

    Lanadelumab

    go.drugbank.com/drugs/DB14597
    ApprovedInvestigational

    Lanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection.

  2. Drug

    Trilaciclib

    go.drugbank.com/drugs/DB15442
    ApprovedInvestigational

    Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for extensive stage...

  3. Drug

    Ranibizumab

    go.drugbank.com/drugs/DB01270
    ApprovedInvestigational

    [L41399] In August 2022, other biosimilars CIMERLI, RAIVISIO, and RANOPTO were approved by the FDA, EC, and Health Canada respectively.[L42625,L43513,L49141] … [A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO.

  4. Drug

    Elexacaftor

    go.drugbank.com/drugs/DB15444
    ApprovedInvestigational

    Elexacaftor (previously VX-445) is a small molecule, next-generation corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. … [A187361] Elexacaftor, along with [VX-659], was designed to fill the need for an efficacious CF therapy for patients who are heterozygous for _F508del-CFTR_ and a gene that does not produce protein or

  5. Drug

    Gefapixant

    go.drugbank.com/drugs/DB15097
    Approved

    [L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601] … It received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications.

  6. Drug

    EA-230

    go.drugbank.com/drugs/DB19114
    Investigational

    EA-230 is under investigation in clinical trial NCT03145220 (Immunomodulation of EA-230 Following On-pump Coronary Artery Bypass Grafting (CABG)).

  7. Drug

    Triflusal

    go.drugbank.com/drugs/DB08814
    ApprovedWithdrawn

    The benefits of this agent are the lack of action over the arachidonic acid pathway, the driven production of nitric oxide and the increase of cyclic nucleotide concentration on endothelial cells.

  8. Drug

    Stannous fluoride

    go.drugbank.com/drugs/DB11092
    ApprovedInvestigational

    It is an FDA-approved over-the-counter product.

    Products: H E B Restore and Defend, Pro-Den Rx
  9. Drug

    Omadacycline

    go.drugbank.com/drugs/DB12455
    ApprovedInvestigational

    Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent

  10. Drug

    Entacapone

    go.drugbank.com/drugs/DB00494
    ApprovedInvestigational

    Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxyl...

    Synonyms: (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamideMixtures: LEV/CAR/EN AL100/25/200, LEV/CAR/EN AL200/50/200